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Pancreatic ductal adenocarcinoma is characterized by a prominent fibroinflammatory stroma with both tumor-
promoting and tumor-suppressive functions. The pancreatic stellate cell (PSC) is the major cellular stromal component
and the main producer of extracellular matrix proteins, including collagens, which are degraded by metalloproteinases
(MMPs). PSCs interact with cancer cells through various factors, including transforming growth factor (TGF)β and
interleukin (IL)-1α. The role of TGFβ in the dual nature of tumor stroma, i.e., protumorigenic or tumor suppressive, is
not clear. We aimed to investigate the roles of TGFβ and IL-1α in the regulation of MMP profiles in PSCs and the
subsequent effects on cancer cell migration. Human PSCs isolated from surgically resected specimens were cultured
in the presence of pancreatic cancer cell lines, as well as IL-1α or TGFβ. MMP production and activities in PSCs were
quantified by gene array transcripts, mRNA measurements, fluorescence resonance energy transfer–based activity
assay, and zymography. PSC-conditioned media and pancreatic cancer cells were included in a collagen matrix cell
migration model. We found that production of IL-1α by pancreatic cancer cells induced alterations in MMP and tissue
inhibitors of matrix metalloproteinase (TIMP) profiles and activities in PSCs, upregulated expression and activation of
MMP1 and MMP3, and enhanced migration of pancreatic cancer cells in the collagen matrix model. TGFβ
counteracted the effects of IL-1α on PSCs, reestablished PSC MMP and TIMP profiles and activities, and inhibited
migration of cancer cells. This suggests that tumor TGFβ has a role as a suppressor of stromal promotion of tumor
progression through alterations in PSC MMP profiles with subsequent inhibition of pancreatic cancer cell migration.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal
forms of cancer, with a mortality rate approaching the rate of
incidence and with a 5-year survival rate below 5% [1]. Despite
advances in the understanding of the genomics of the disease and
identification of novel potential therapeutic targets [2], a real
improvement in clinical outcome has not been achieved [3]. PDAC
is largely resistant to all forms of conventional chemotherapy and
radiation therapy. Surgical resection remains the only treatment with
a potential for cure, although only 15% to 20% of the patients are
eligible for resection [1]. Even following a successful resection, most
patients develop disease recurrence within a year, indicating that
additional treatment strategies are needed to improve survival [4].
448 MMP and TIMP Expression in Human PSCs Tjomsland et al. Neoplasia Vol. 18, No. 7, 2016A characteristic feature of PDAC is a prominent desmoplastic
reaction, characterized by a dense fibroinflammatory stroma that
surrounds the malignant cells [5]. The tumor stroma is composed of
cellular elements and extracellular matrix (ECM) proteins. The
pancreatic stellate cell (PSC) is the principal cell type of the
desmoplastic stroma in PDAC and the major producer and regulator
of the ECM [6,7]. Upon activation, PSCs secrete excessive amounts
of collagen, fibronectin, and matrix-degrading enzymes such as matrix
metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of
matrix metalloproteinases (TIMPs) [8–10]. It has recently become
clear that the tumor stroma has both tumor-promotive and
tumor-suppressive effects in PDAC [11]. Although the precise
mechanisms of the mutual interactions between cancer cells and
stromal elements are only partially known, proteolytic and structural
modifications of the ECM are believed to be involved [12,13].
Matrix-degrading factors such as MMPs are the most important
enzymes that cause ECM remodeling [14] and may provide favorable
conditions for migration of cancer cells and as such facilitate invasive
cancer growth [15].
Interleukin (IL)-1α is abundantly present in the tumor microen-
vironment and exerts multiple effects in the tumor stroma, including
tumor-promoting effects [16,17]. In PDAC, IL-1α is expressed
exclusively by the malignant cells of the tumor and is immunohis-
tochemically detected in the majority of tumors [18,19]. IL-1α–
positive PDAC cancer cell lines were previously shown to induce a
specific inflammatory profile of the PSCs, and under IL-1α
stimulation, PSCs induce migration of PDAC cells in vitro [18,20].
Moreover, induction of IL-1α expression in PDAC cell lines has been
shown to promote metastatic and invasive behavior in an orthotopic
mouse model [21].
Transforming growth factor (TGF)β controls numerous biological
functions and has both pro- and antitumor activities depending on
the context. In early stages of carcinogenesis, the effect is usually
tumor suppressive, whereas in later stages of cancer progression,
TGFβ has tumor-promotional effects [22]. In PDAC, TGFβ is a key
signaling mediator involved in stroma-tumor cross talk,
epithelial-to-mesenchymal transition, and tumor invasion [23–25].
The overexpression of TGFβ and its receptors on cancer cells and in
the tumor microenvironment has made this cytokine an attractive
target for therapeutic intervention [26]. However, few data exist
regarding distinct effects of TGFβ targeted therapy on cancer cells and
stroma cells, respectively [27].
In the present study, we examined MMP and TIMP production by
human PSCs and its regulation by IL-1α and TGFβ. We found that
IL-1α induced a specific MMP/TIMP profile in the PSCs, which
facilitated migration of pancreatic cancer cells in a collagen matrix
model, and that these effects were suppressed by TGFβ. The data
suggest an important role for TGFβ as a suppressor of PSC-induced
migration of pancreatic cancer cells and add to the complexity of
stroma-tumor interactions with potential implications for
stroma-targeted therapies in pancreatic cancer.
Material and Methods
Patients
The study protocol and patient consent documents were approved
by the Regional Committee for Medical and Health Research Ethics
(REC South East, project number 2010/694a) and were in
compliance with the Helsinki Declaration. Written informed consentwas obtained from all study participants. The study included only
adults.
Cells, Isolation, and Culture
Human PSCs were isolated from pancreatic tumor tissue obtained
during pancreatic surgery (pancreatoduodenectomies) from patients
with resectable pancreatic ductal adenocarcinoma. PSCs were
cultured by the outgrowth method as developed by Bachem et al.
[28] and described elsewhere [29]. The purity of the PSCs was
assessed by morphology and cytofilament staining of α-SMA and
vimentin. None of the cells were positive for CK7 or CK20. All
experiments were performed using cell populations between passage 4
and 8. The primary PDAC cell line PC013 was propagated from
PDAC tumor tissue samples as described elsewhere [18]. BxPC-3 and
CAPAN2 were purchased from ATCC (Manassas, VA). All cell lines
were cultured in Dulbecco’s modified Eagle’s medium containing
4.5 g/l of glucose (DMEM). The media were supplemented with
100 μg/ml of Pen-Strep, Glutamax, and 10% fetal bovine serum
(FBS) (Life Technologies, Carlsbad, CA). For the co-culture assays,
6 × 105 CAPAN2, PC013, or BxPC-3 cells were seeded per
Transwell insert (Corning Incorporated, Corning, NY) and cultured
for 24 hours before moving the inserts into 6-well plates containing a
confluent layer of PSCs. Cancer cells and PSCs were co-cultured for
72 hours before analyzing gene expression. For IL-1α (Biolegend, San
Diego, CA), recombinant interleukin-1 receptor antagonist IL-1RA
(Anakinra; gift from Swedish Orphan Biovitrum AS, Norway) and
TGFβ stimulation, the PSCs were cultured to confluence, washed
with NaCl, and cultured in serum-free DMEM supplemented with
1 ng/ml of IL-1α, and/or 2 ng/ml of TGFβ and 10 μg/ml of IL-1Ra.
Supernatants were harvested after 4 days of culture, centrifuged, and
stored at −30°C until use.
Chemicals
Dulbecco’s modified Eagle's medium, glutamine, and Pen-Strep
(10,000 U/ml) were obtained from Lonza (Verviers, Belgium).
Amphotericin was purchased from Life Technologies (Carlsbad, CA).
Recombinant human transforming growth factor-β1 was obtained
from R&D Systems Europe, Ltd (Abingdon, England). [6-3H]
thymidine (20-30 Ci/mmol) was purchased from PerkinElmer
(Boston, MA). Antibodies against IL-1R1 were obtained from
Millipore (Billerica, MA), and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was obtained from Cell Signaling Technology
(Boston, MA). Secondary antibodies were purchased from Bio-Rad
Laboratories (Hercules, CA), LI-COR Biosciences (Lincoln, NE),
and Jackson Immunoresearch (Baltimore, PA).
Gene Expression Analysis
Gene transcription-profiling data set was obtained from previous
studies (Tjomsland, E-MEXP-2826, https://www.ebi.ac.uk/
arrayexpress). Subsequent data analysis involved the normalization
of array values using RMA software. The gene array data were
obtained from single-cultured and fluorescence-activated cell sorting–
separated PSCs cultured in direct contact with the primary PDAC cell
line PC013 [18].
RNA Extraction and Real-Time Quantitative Reverse
Transcriptase Polymerase Chain Reaction (qPCR)
Total RNA was prepared from the samples using RNA Easy Mini
kit (Qiagen Inc., Valencia, CA), and cDNA was synthesized with
SuperScript III Reverse Transcriptase First-Strand cDNA Synthesis
Table 1. MMP and TIMP Gene Profiles in PSCs and in PSCs Co-Cultured with Cancer Cells
MMPs TIMPs
Gene Expression Values Gene Expression Values Gene Expression Values
Gene Name Single PSCs Co-Cultured PSCs Gene Name Single PSCs Co-Cultured PSCs Gene Name Single PSCs Co-Cultured PSCs
MMP1 1267 7238 MMP16 ND ND TIMP1 14,279 15,101
MMP2 8068 5018 MMP17 105 110 TIMP2 4206 4797
MMP3 6500 10,180 MMP19 114 ND TIMP3 1517 1313
MMP7 ND ND MMP20 ND ND TIMP4 ND ND
MMP8 ND ND MMP21 ND ND
MMP9 ND ND MMP23 ND ND
MMP10 235 390 MMP24 ND ND
MMP11 177 377 MMP25 ND ND
MMP12 ND ND MMP26 ND ND
MMP14 576 490 MMP27 ND ND
MMP15 ND ND MMP28 130 235
Gene transcription-profiling data set was obtained from previous studies. The data show mean expression values for each MMP and TIMP in single-cultured PSCs and fluorescence-activated cell sorting–
separated PSCs cultured in direct contact with the primary PDAC cell line PC013. The cutoff gene expression value was set to 100, and values below cutoff were regarded as negative expression. ND, not
detectable.
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Carlsbad, CA). Quantitative PCR was performed with Platinum
SYBR Green Master Mix (Life Technologies, Carlsbad, CA) on 7900A
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Figure 1. IL-1α expression in pancreatic cancer tissue and cell li
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used. GAPDH was used as a housekeeping gene. The primers were
designed using Primer-BLAST [30]. All reactions were performed in
triplicates including nontemplate controls. The results were analyzed
using the ΔΔCt method [31]. The relative gene expression raw data
were normalized to GAPDH and presented as relative gene expression
for each gene.
ELISA
The levels of IL-1α in supernatants from PC013, BxPC-3, and
CAPAN2 cells were assessed after culturing the cells for 3 days in
DMEM supplemented with 1% FBS. The supernatants were
harvested, and the concentration of IL-1α was measured by ELISA
according to the manufacturer’s protocol (Biolegend, San Diego,
CA).
Casein Zymography
MMP3 proteolytic activities were detected by casein substrate
zymography. Conditioned media from control, IL-1α (1 ng/ml), and
a combination of IL-1α and TGFβ (2 ng/ml) were concentrated by
Amicon Ultracel 3K centrifugal filter device (Millipore, Billerica,
MA). The concentrated conditioned media were mixed in nonre-
ducing sample buffer containing SDS, glycerol, and bromophenol
blue and subsequently subjected to electrophoresis on 12%
polyacrylamide SDS gels containing 0.1% casein (Sigma Aldrich,
Oslo, Norway). After electrophoresis, the polyacrylamide gels were
washed three times in 2.5% Triton X-100 for 30 minutes to remove
all traces of SDS. The gels were rinsed in distilled water for 5 minutes
and finally incubated at 37°C for 20 hours in developing buffer
containing 50 mM Tris HC (pH 7.5), 5 mM CaCl2, 0.02% Brij-35,
and 200 mM NaCl3. The gels were stained with 0.125% Coomassie
brilliant blue G-250 (Sigma Aldrich, Oslo, Norway) in 40%
methanol and 10% acetic acid solution for 2 hours and destained
with 40% methanol and 10% acetic acid solution. The MMP3 level
was identified as clear zones of lysis against a blue background. For the
quantification of MMP3 levels, images were acquired using
ChemiDoc XRS (Bio-Rad Laboratories, Hercules, CA) and processed
using FIJI software as described by Schindelin et al. [32].
MMP1 Activity Assay
The MMP1 activity in conditioned media of control, IL-1α
(1 ng/ml), and a combination of IL-1α and TGFβ (2 ng/ml) wasMMP1
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Figure 2. IL-1α regulates MMP and TIMP expression in PSCs. PSCs
were cultured in the presence or absence of IL-1α. The relative
gene expression of (A) MMP1, MMP2, and MMP3 and (B) TIMP1,
TIMP2, and TIMP3 were analyzed and compared with nonstimu-
lated PSCs. *P b .05, **P b .005, and ***P b .001.determined using the SensoLyte Plus 520 MMP-1 Assay Kit
(AnaSpec, San Jose, CA). Briefly, the conditioned media were
collected from PC013, BxPC-3, and CAPAN2 cells after 3 days of
culture in DMEM supplemented with 1% FBS. One hundred
microliters of conditioned media was added to MMP1 antibody
precoated microplate wells. The MMP1 substrate 5-FAM/QXL520
fluorescence resonance energy transfer (FRET) peptide was added to
the wells, and after 16 hours of incubation, the fluorescence intensity
representing the MMP1 activity was measured at 490/520-nm
wavelength using EnVision Multilabel Reader (Perkin Elmer,
Waltham, MA).
Immunohistochemistry and Immunocytochemistry
Formalin-fixed, paraffin-embedded PDAC tissue and cultured
cancer cell lines were immunostained with anti-human IL-1α
antibodies (ab7632, ABcam, Cambridge, UK), visualized by Alkaline
Phosphatase Red (Biocare Medical, Concord, CA), and counter-
stained with methyl green (Sigma Aldrich, Oslo, Norway) as
described elsewhere [18].
Collagen I Migration Assay
Collagen I infiltration and migration assay was assessed by seeding
2 × 106 PC013, BxPC-3, or CAPAN2 cells in 10% FBS DMEM
overnight. The medium was replaced the next day with fresh
serum-free DMEM supplemented with 2 μCi/ml [6-3H] thymidine.
Collagen I matrix gels were prepared by diluting bovine collagen I
(Life Technologies, Carlsbad, CA) in serum-free control medium and
supernatants from PSCs cultured in the presence of control (no
supplements), IL-1α (1 ng/ml), and TGFβ (2 ng/ml) as single agents
or in combination, and 10 μMof the broad-spectrumMMP inhibitor
batimastat (R&D Systems Europe, Ltd, Abingdon, England). Cancer
cells were added to a final concentration of 1 × 106 cells/ml and a
collagen I concentration of 0.3%. Fifty microliters of collagen I gel
mixture containing 5 × 104 cells was distributed to cell culture inserts
(pore size 8.0 μM) placed in 24-well plates. The inserts were
incubated at 37°C for 30 minutes before adding DMEM
supplemented with 10% FBS to the bottom compartment. After
24 hours of incubation at 37°C, the cells were harvested by applying a
cotton stick on each side of the insert surface, and [6-3H] thymidine
incorporation was determined by liquid scintillation (Packard
Tri-Carb 1900 TR). Infiltration and migration of cells were
calculated as [6-3H] thymidine incorporation detected on the bottom
side divided by total incorporation.
Statistical Analysis
The statistical analysis was performed with GraphPad Prism 5
(GraphPad Software). P b .05 was considered statistically significant,
and error bars indicate standard error of the mean. The data were
analyzed by paired t test, and multiple comparisons were analyzed
using analysis of variance including Bonferroni correction.
Results
MMP and TIMP Profiles in PSCs
To establish MMP and TIMP expression profiles in PSCs, we
analyzed gene array data from PSCs cultured alone and PSCs
co-cultured with the primary pancreatic cancer cell line PC013. The
gene array data indicate expression primarily of MMP1, MMP2, and
MMP3 in PSCs (Table 1). Direct co-culture with PC013 cells
increased the expression of MMP1 and MMP3 and decreased
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Figure 3. IL-1α–positive PDAC cell lines affect PSC expression of MMP1, MMP2, MMP3, TIMP2, and TIMP3. The PDAC cell lines
PC013, BxPC-3, and CAPAN2 were co-cultured with PSCs in the presence or absence of IL-1RA. The relative gene expression of MMP1
(A), MMP2 (B), MMP3 (C), TIMP1 (D), TIMP2 (E), and TIMP3 (F) was analyzed in PSCs after 3 days of co-culture. *P b .05, **P b .005, and
****P b .001.
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array data, expression of MMP1, MMP2, or MMP3 was not detected
in the pancreatic cancer cells (data not shown). Expression of TIMP1,
TIMP2, and TIMP3 was detected in PSCs, and only minor changes
in expression were observed after co-culture with PC013 cancer cells.
The gene array data did not indicate any expression of TIMP4
(Table 1).
PDAC Cell Lines Express and Secrete IL-1α
IL-1α was immunohistochemically confirmed to be absent in
healthy pancreatic tissue (Figure 1A) and found to be exclusively
expressed by malignant cells in PDAC tissue (Figure 1B). PC013, a
primary PDAC cell line established from the same tumor as shown
in Figure 1B, was investigated by immunocytochemistry for further
characterization. The results demonstrated negative binding of
secondary fluorescent antibodies (control) (Figure 1C), positive
expression of the epithelial cell marker Epcam (Figure 1D), and
intracellular expression of IL-1α, primarily in the cell cytoplasm
(Figure 1E). Moreover, the PDAC cell lines were assessed for gene
expression and secretion of IL-1α. The primary PDAC cell line
PC013 showed strong gene expression, BxPC-3 expressed moderate
levels, whereas CAPAN2 was found to be IL-1α negative
(Figure 1F). The secreted levels of IL-1α confirmed the gene
expression data after 3 days of culture, showing the highest levels in
supernatants from PC013, lower levels in supernatants from
BxPC-3 cells, and absence of IL-1α in supernatants from
CAPAN2 cells (Figure 1G).IL-1α Regulates Expression of MMPs and TIMPs in PSCs
To evaluate the role of IL-1α in the expression of MMPs and
TIMPs, PSCs were cultured in the presence of 1 ng/ml of IL-1α.
Gene expression levels of MMP1 (P b .005) and MMP3 (P = .006)
increased significantly by 9- and 33-fold, respectively, whereas the
expression of MMP2 decreased significantly (P b .005) by 2.5-fold
compared with untreated PSCs (Figure 2A). Gene expression of
MMP9 was not detected in PSCs (data not shown). IL-1α reduced
the expression levels of TIMP2 (P = .02) and TIMP3 (P = .01)
significantly by three-fold each, whereas expression of TIMP1 was not
significantly reduced (Figure 2B).IL-1α from PDAC Cell Lines Regulates MMP and TIMP
Expression in PSCs
To investigate the involvement of IL-1α in PDAC cell induction of
MMPs and TIMPs, IL-1α–positive (PC013 and BxPC-3) and
IL-1α–negative (CAPAN2) cancer cell lines were cultured alone or in
co-culture with PSCs. PC013 and BxPC-3 cells induced the
expression of MMP1 and MMP3 in PSCs, whereas CAPAN2 did
not affect the expression. All tested PDAC cell lines reduced the gene
expression levels of MMP2 in the PSCs (Figure 3, A–C). Co-culture
with PC013 and BxPC-3 reduced PSC gene expression of TIMP1 to
3, whereas co-culture with CAPAN2 caused a decrease only in the
expression of TIMP1 and 2 (Figure 3, D–F). IL-1α–expressing
PDAC cell lines exerted the most pronounced effects on the PSCs
gene expression profiles of MMPs and TIMPs. To investigate the
involvement of IL-1α in the regulation of MMP1 and TIMP
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Figure 4. TGFβ inhibits the effects of IL-1α on PSC expression of MMPs and TIMPs. PSCs were cultured in the presence of IL-1α (1 ng/ml),
TGFβ (2 ng/ml), or a combination of both cytokines. Gene expression of MMP1 (A), MMP2 (B), MMP3 (C), TIMP1 (D), TIMP2 (E), and
TIMP3 (F) was analyzed and normalized to untreated controls. Supernatants were harvested from PSCs incubated with IL-1α (1 ng/ml), a
combination of IL-1α (1 ng/ml) and TGFβ (2 ng/ml), and untreated control PSCs. MMP-1 activity was detected by substrate 5-FAM/QXL520
FRET peptide assay (G), and data are shown in pg/ml of supernatant. Active MMP3was detected by casein zymography and quantified by
FIJI software (H). A representative zymogram from one experiment is shown. *P b .05, **P b .005, and ***P b .001.
452 MMP and TIMP Expression in Human PSCs Tjomsland et al. Neoplasia Vol. 18, No. 7, 2016expression, we neutralized the effect of IL-1α in the medium by
adding rhIL-1RA to the co-cultures. By blocking the effects of IL-1α,
the cancer cells lost their ability to induce PSC expression of MMP1
andMMP3. Moreover, IL-1α inhibition also increased the expression
of MMP2 in the PSCs. IL-1RA did not affect the reduced expression
of TIMP1 but enhanced the expression of TIMP2.
TGFβ Inhibits IL-1α Regulated PSC Expression of MMP1,
MMP2, MMP3, TIMP2, and TIMP3
To investigate the influence of TGFβ on IL-1α–induced MMP
regulation, we incubated PSCs in the presence of IL-1α (1 ng/ml) and
TGFβ (2 ng/ml), alone or in combination. TGFβ significantly
inhibited the effects of IL-1α on PSC expression of MMP1 (P b .001)
and MMP3 (P b .001), whereas it reduced the inhibiting effects of
IL-1α on PSCs expression of MMP2 (Figure 4, A–C). As a single
agent, TGFβ significantly induced the expression of TIMP1 (P b
.001) and TIMP3 (P b .001), whereas IL-1α as a single agent reduced
the levels of TIMP2 and TIMP3 (P b .001). When combining IL-1αand TGFβ, no effects on TIMP1 and TIMP3 expression were
observed compared with unstimulated PSCs. In contrast, the
combination of the two factors did not affect the inhibiting effects
of IL-1α on the expression of TIMP2 (Figure 4, D–F). To further
confirm the regulatory effects of TGFβ on IL-1α signaling in PSCs,
we analyzed the MMP1 and MMP3 activity in supernatants from
PSCs cultured in the presence of 1 ng/ml of IL-1α or a combination
of 1 ng/ml of IL-1α and 2 ng/ml of TGFβ. Collagen type I
zymography revealed expression of one strong band, which could
indicate predominant expression of pre-MMP1 (data not shown).
MMP-1 substrate 5-FAM/QXL520 FRET peptide assay was
employed to further evaluate the expression of active MMP in the
samples. The results showed no expression of active MMP1 in
supernatants from untreated PSCs. Activated MMP1 was detected in
supernatant from PSCs exposed to 1 ng/ml of IL-1α, whereas the
presence of 2 ng/ml of TGFβ significantly (P b .05) reduced this
expression (Figure 4G). Active MMP3 was detected by quantification
of casein zymograms, which revealed significantly increased MMP3
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Figure 5. TGFβ inhibits IL-1α–induced cancer cell migration in collagen type I matrix. [6-3H] thymidine-incorporated pancreatic cancer cell
lines (PC013, BxPC-3, or CAPAN2) were added to the collagen matrix migration system. Collagen type I matrix gels were prepared with
either serum-free medium or PSC-conditioned medium. The conditioned medium was prepared by culturing the PSCs in the presence or
absence of 1 ng/ml of IL-1α and 2 ng/ml of TGFβ as single agents or in combination (A–D). Representative crystal violet staining of BxPC-3
cells from one experiment is shown in figure D. To confirm the role of MMPs in the migration of the PDAC cell lines, the broad-spectrum
MMP inhibitor batimastat was added to the migration system (E–F). Pancreatic cancer cell migration is presented as percent [6-3H]
thymidine incorporation from the bottom side of the membrane compared with total [6-3H] thymidine incorporation (top side and bottom
side) and normalized to respective controls. *P b .05, **P b .005, and ***P b .001.
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unstimulated PSCs. Supernatants from PSCs exposed to a combina-
tion of 1 ng/ml of IL-1α and 2 ng/ml of TGFβ showed significantly
decreased MMP3 activity compared with PSCs stimulated with
IL-1α only (Figure 4H).
TGFβ Inhibits IL-1α–Induced Cancer Cell Migration in
Collagen Type I Matrix
MMP1 has previously been shown to play a major role in collagen
type I degradation [33]. Our findings show increased expression of
MMP1 after stimulating PSCs with IL-1α or IL-1α–positive PDAC
cell lines. We investigated whether IL-1α–stimulated PSCs influence
the migration of cancer cells in a collagen type I matrix and whether
TGFβ can counteract the effect of IL-1α (Figure 5, A–D). The
collagen matrix gels containing PSC-conditioned medium increased
the migration of PC013, BxPC-3, and CAPAN2 cells compared with
control matrix. Collagen type I matrix containing conditioned
medium from IL-1α–stimulated PSCs enhanced the migration of thePDAC cell lines. In contrast, collagen type I matrix containing
conditioned medium from TGFβ-stimulated PSCs had no additional
effects on PDAC cell migration compared with unstimulated PSCs.
However, conditioned medium from PSCs stimulated with a
combination of both TGFβ and IL-1α significantly reduced cancer
cell migration. To confirm the role of MMPs in the migration of the
PDAC cell lines, the broad-spectrum MMP inhibitor batimastat was
added to the collagen type I matrix (Figure 5, E–G). Batimastat
virtually abolished the stimulatory effects exerted by IL-1α–
stimulated PSCs on migration of PC013, BxPC-3, and CAPAN2
in a collagen type I matrix.
Discussion
In the present study, we demonstrate that pancreatic cancer cells
through an IL-1α signaling mechanism are able to induce a
tumor-promotive MMP expression profile in human PSCs. The
IL-1α–induced MMP profile, i.e., increased MMP1 and MMP3, is
optimal for degradation of the dominating type I collagen present in
454 MMP and TIMP Expression in Human PSCs Tjomsland et al. Neoplasia Vol. 18, No. 7, 2016the ECM of the desmoplastic tumor stroma. Contrary to the prevailing
paradigm that TGFβ supports tumor progression, we found that
TGFβ suppressed the IL-1α–induced MMP profile in PSCs, which
reduced cancer cell migration in a tumor stroma collagen type I model.
We hypothesized that IL-1α has a role in the remodeling of
extracellular matrix in pancreatic cancer, such that malignant
infiltration is facilitated. Collagen type I is the major component of
ECM and provides structural integrity and mechanical flexibility to
the tumor stroma [34,35]. MMP1 is considered to be the
rate-limiting enzyme in the degradation of collagen type I [33], and
MMP1 derived from cancer-associated fibroblasts appears to facilitate
cancer cell migration and invasive behavior in breast cancer [36].
Furthermore, recent observations in cervical cancer implicate stromal
fibroblasts in cancer cell migration through MMP-2 production and
ECM remodeling [37]. Gene expression of MMP1 and MMP3 was
detected in PSCs, and the expression was further induced by IL-1α or
IL-1α–positive PDAC cell lines. Noteworthy, the cleaved active form
of MMP1 was only detected when PSCs were incubated in the
presence of IL-1α. This is in accordance with previous findings in
cancer tissue, showing MMP1 expression by tumor cells or adjacent
fibroblasts in response to stimulating factors produced by the tumor
cells [38]. Notably, MMP1 is detected at the invasive tumor front,
and overexpression has been associated with poor prognosis in a
variety of advanced cancers, including pancreatic adenocarcinoma
[38,39]. The IL-1α–dependent expression of active MMP1 could be
explained by increased expression of MMP3, which is able to cleave
pro-MMP1 [40]. In the presence of IL-1α, a specific expression
profile was induced in PSCs, which was characterized by increased
expression of MMP1 and MMP3 as well as reduced levels of MMP2,
TIMP2, and TIMP3. TIMP3 has previously been found to
preferentially inhibit the activity of MMP1 and MMP3 [41], and
reduced expression of TIMP3 could enhance their proteolytic
activity, resulting in remodeling of the tumor stroma ECM.
During the first step of cancer cell invasion, the basement
membrane primarily consisting of collagen IV is degraded by
extracellular proteases such as MMP2 and MMP9 [42]. However,
collagen type I is the major ECM component in the tumor stroma,
and ECM remodeling is mandatory for further neoplastic invasion
[34]. Moreover, IL-1α is a pivotal inducer of both MMP1 and
MMP3 expression [43], and induction of IL-1α expression in PDAC
cell lines has been shown to favor their metastatic and invasive
behavior in vitro and in preclinical models [44]. IL-1α has been
detected in the majority of PDAC tumors, and high expression is
associated with poor clinical outcome [18]. This suggests a role for
MMP-dependent degradation in carcinoma invasion. However, all
clinical trials targeting MMPs in pancreatic cancer, such as tanomastat
(inhibiting MMP2, MMP3, MMP9, and MMP13) and marimastat
(inhibiting MMP1, MMP2, MMP7, MMP9, and MMP14), have
remained without clinical benefit when compared with treatment
with gemcitabine alone [45,46]. The lack of specific MMP inhibitors
and a growing list of non-ECM protein substrates for the MMPs may
contribute to their ineffectiveness. However, MMP inhibitors are
suggested to be more efficacious if used in the early stage of tumor
development as MMPs contribute to driving the disease progression
[47]. The failure of MMP inhibitors in the clinic prompts alternative
strategies to target MMP-induced tumor progression. Because we
found that IL-1α induced a specific MMP and TIMP activity profile
in PSCs, inhibitors of this process might possibly represent a novel
strategy for suppression of invasive tumor behavior.In the present study, we verified a critical role for the IL-1α–
induced MMP and TIMP profiles in a collagen type I migration
model. When adding a broad-spectrum inhibitor of MMP activity
(batimastat), the stimulatory effect on migration exerted by IL-1α/
PSC signaling was abolished, suggesting that the effects of PSCs on
migration are mediated through an altered activity of MMPs.
Furthermore, the major finding in the present study is that TGFβ
inhibited IL-1α/PSC-induced cancer cell migration. This is in
accordance with the notion that TGFβ exerts tumor-suppressive
effects through the regulation of stromal functions and, furthermore,
that the ability of TGFβ to inhibit ECM remodeling through IL-1α
could be an essential tumor-protective mechanism.
The role of TGFβ in the tumor stroma is highly complex [48].
TGFβ activates PSCs and is a key player in pancreatic fibrosis in both
pancreatitis and pancreatic cancer [49]. TGFβ is also essential in the
upregulation of the characteristic marker αSMA in PSCs [50].
Recently, high expression of αSMA in the tumor stroma was found to
correlate with better overall survival in PDAC patients, which further
supports a cancer protective role of the tumor stroma in PDAC [51].
TGFβ regulates the stroma by production, degradation, and
accumulation of ECM proteins; inhibits the synthesis of
matrix-depleting proteins such as MMPs in desmoplastic pancreatic
cancer tissue; and upregulates collagens I to V, suggesting a protective
physiological response in the stroma [49,52,53]. In contrast, collagen
I secreted from PSCs has also been shown to promote pancreatic
cancer cell migration through upregulation of cell adhesion
molecules, such as N-cadherin and α2b1 integrins [54,55]. This
emphasizes the complexity of pleiotropic factors and their diverse
roles in cancer progression related to stroma composition.
Several lines of evidence indicate that tumor stroma has a dual
nature with respect to cancer progression. In contrast to the
previously dominating view suggesting that PDAC stroma, including
PSCs, has largely tumor-promoting effects, recent evidence also
supports a tumor-suppressor function of PDAC stroma in pancreatic
cancer. Ozdemir et al. showed that the tumor stroma might act to
restrain, rather than support, pancreatic cancer progression [51].
Furthermore, two studies employing different strategies for depletion
of stromal cells in pancreatic tumors through targeting of the sonic
hedgehog pathway resulted in poorly differentiated tumor histology,
accelerated rather than reduced tumor progression, and reduced
survival [56,57]. In contrast to extensive ligand-induced stromal
disruption, reprogramming of PSCs resulting in stroma remodeling
represents an alternative therapeutic approach [58]. These observa-
tions support the notion that the impact of stroma in pancreatic
cancer might be highly circumstantial, depending on temporal and
spatial events and the functional status of stromal components and
malignant cells. Furthermore, the paradigm that tumor stroma is
cancer promoting with stroma depletion as a possible therapeutic
approach now appears more suitably replaced by the concept that
tumor stroma has a dual nature and that stroma remodeling rather
than stromal ablation might represent a preferred therapeutic
approach.
In the present study, we have explored one mechanism involved in
stromal suppression of tumor cell migration. MMP and TIMP
profiles and activities are crucial factors in tumor stroma remodeling.
This is mediated by IL-1α from the tumor cells. Our data show that
TGFβ counteracts the tumor-supportive stromal MMP and TIMP
profiles and thereby inhibits cancer cell migration by inhibiting
IL-1α–induced effects in PSCs. This suggests that tumor TGFβ has a
Neoplasia Vol. 18, No. 7, 2016 MMP and TIMP Expression in Human PSCs Tjomsland et al. 455role as a suppressor of stromal promotion of tumor progression. These
findings underscore the notion that tumor stroma in pancreatic
cancer is a multicomponent entity where results of intervention
strategies are highly dependent on context. Furthermore, this notion
could at least partly explain the lack of clinical benefit of therapies
targeting tumor stroma.
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